-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Stock Rating Lowered by TheStreet
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Stock Rating Lowered by TheStreet
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note published on Tuesday morning, TheStreetRatingsTable reports.
A number of other brokerages have also recently commented on CALT. Kepler Capital Markets began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They set a buy rating for the company. Pareto Securities began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They set a buy rating for the company.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Stock Up 1.9 %
Shares of NASDAQ:CALT opened at $15.75 on Tuesday. The business has a 50-day moving average price of $18.21 and a 200 day moving average price of $17.80. Calliditas Therapeutics AB has a 12-month low of $12.55 and a 12-month high of $32.24. The company has a market capitalization of $465.87 million, a price-to-earnings ratio of -6.33 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64.
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC increased its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,762 shares of the company's stock after purchasing an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned approximately 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 at the end of the most recent quarter. Institutional investors own 2.94% of the company's stock.Calliditas Therapeutics AB (publ) Company Profile
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Further Reading
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
TheStreet cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) from a c- rating to a d rating in a research note published on Tuesday morning, TheStreetRatingsTable reports.
据The StreetRatingsTable报道，在周二上午发布的一份研究报告中，华尔街将Calliditas治疗公司(Publ)(纳斯达克代码：CALT-GET评级)的股票从C级下调至D级。
A number of other brokerages have also recently commented on CALT. Kepler Capital Markets began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They set a buy rating for the company. Pareto Securities began coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They set a buy rating for the company.
其他一些券商最近也对CALT发表了评论。开普勒资本市场在6月16日星期四的一份报告中开始报道Calliditas Treateutics AB(Publ)。他们为该公司设定了买入评级。帕累托证券在6月2日星期四的一份报告中开始报道Calliditas Treateutics AB(Publ)。他们为该公司设定了买入评级。
Calliditas Therapeutics AB (publ) Stock Up 1.9 %
Calliditas Treateutics AB(Publ)股价上涨1.9%
Shares of NASDAQ:CALT opened at $15.75 on Tuesday. The business has a 50-day moving average price of $18.21 and a 200 day moving average price of $17.80. Calliditas Therapeutics AB has a 12-month low of $12.55 and a 12-month high of $32.24. The company has a market capitalization of $465.87 million, a price-to-earnings ratio of -6.33 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64.
纳斯达克：CALT的股票周二开盘报15.75美元。该业务的50日移动均线价格为18.21美元，200日移动均线价格为17.80美元。Calliditas Treateutics AB的12个月低点为12.55美元，12个月高位为32.24美元。该公司市值为4.6587亿美元，市盈率为-6.33倍，贝塔系数为1.63。该公司的流动比率为5.32，速动比率为5.32，债务权益比率为0.64。
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
对冲基金买入Calliditas Treateutics AB(Publ)
Calliditas Therapeutics AB (publ) Company Profile
Calliditas Treateutics AB(Publ)公司简介
(Get Rating)
(获取评级)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家临床阶段的生物制药公司，专注于识别、开发和商业化用于孤儿适应症治疗的药物产品，最初的重点是肾脏和肝脏疾病。它提供Nefecon，一种口服布地奈德制剂，是一种治疗自身免疫性肾病免疫球蛋白A肾病的免疫抑制剂。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- 免费获取StockNews.com关于Calliditas Treateutics AB(Publ)(CALT)的研究报告
- 石油和天然气股票：投资可再生能源的安全途径
- 这些绿色能源公司适合你的投资组合吗？
- 希捷科技的宿醉何时才能结束？
- 安相能源有足够的动力继续提高动力吗？
- 独一无二的氢燃料电池库存
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Calliditas Treateutics AB(Publ)和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧